Stone Adam Leo 4

What Happened

• Adam Stone, a director of Solid Biosciences, was granted a derivative award for 77,500 shares on June 10, 2026. The filing reports the grant price as $0.00 (this is a stock option/award, not an open-market purchase or sale).
• This is an award/grant (transaction code A) — not an immediate sale or cash purchase — so there was no cash exchanged and no immediate change in liquid ownership.

Key Details

• Transaction date: 2026-06-10; Filing date: 2026-06-11 (timely).
• Instrument: derivative award/option for 77,500 shares; reported acquisition price $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote (vesting): The option vests in full on the earlier of the one-year anniversary of the grant and immediately prior to the issuer’s next annual meeting after the grant date, and will vest 100% upon specified change-in-control events.

Context

• This is a grant of equity compensation to a director. Such awards are common for executive/director compensation and do not indicate an immediate market purchase or sale.
• Because it’s a derivative award, the options must vest (and potentially be exercised) before they convert into transferable shares or realized value.